SCHEMBL24285859

SCHEMBL24285859

Nc1nc2ccc(-c3ccc4[nH]ccc4c3)cn2c1C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ CYP17A1 P05093 1/20 0.43
▸ CYP11B1 P15538 1/20 0.43
▸ CYP11B2 P19099 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ LRRK2 Q5S007 2/20 0.42
▸ CYP2A6 P11509 1/20 0.41
▸ PTGS2 P35354 1/20 0.39
▸ PSMB8 P28062 1/20 0.39
▸ DYRK3 O43781 3/20 0.38
▸ CCNT1 O60563 3/20 0.38
▸ CDK9 P50750 3/20 0.38
▸ CDK5 Q00535 3/20 0.38
▸ DYRK1A Q13627 3/20 0.38
▸ CDK5R1 Q15078 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24285974 0.82 RIPK1 (0.50) LRRK2DYRK3CCNT1CDK9CDK5
SCHEMBL24286014 0.78 USP7 (0.32) NPC1LRRK2
SCHEMBL24285941 0.78 TDO2 (0.33) PIK3CDMTOR
SCHEMBL24285992 0.77 BRAF (0.33) NPC1KDR
SCHEMBL24286245 0.76 MET (0.44) NPC1ADORA2AKDR
SCHEMBL24286069 0.76 DYRK1A (0.48) CA12CA2CYP2A6CDK9DYRK1A
SCHEMBL24286081 0.75 PIM1 (0.30) SRC
SCHEMBL24285948 0.73 MAP3K14 (0.43) MAPTDYRK1A
SCHEMBL24285976 0.73 LRRK2 (0.42) CA12CA1CA2CA9HDAC2
SCHEMBL29537329 0.73 LRRK2 (0.42) CA12CA1CA2CA9HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 CA12 3721/4885CA1 2239/4885CA2 532/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 CA12 3721/4885CA1 2239/4885CA2 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback